Anti-Cancer Drugs
Title Abbreviation
Anticancer Drugs
Electronic ISSN
1473-5741
Readership
Clinical Pharmacists, Clinical Pharmacologists, Oncologists, Pharmacists, Pharmacologists
Scope
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
Sponsoring Association(s)
No associations affiliated with this journal
Publisher Name
Wolters Kluwer Health - Lippincott Williams & Wilkins - UK
Impact Factor
JCR Categories/Rank
Circulation
Electronic Circulation
Submission to Acceptance
Acceptance to Online Publication
Acceptance to Print Publication
Rejection Rate
Frequency
Journal Contact
Author Submission Guidelines